John Segreti to Daptomycin
This is a "connection" page, showing publications John Segreti has written about Daptomycin.
Connection Strength
1.782
-
Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clin Ther. 2010 Sep; 32(10):1713-9.
Score: 0.383
-
Empirical therapy for serious Gram-positive infections: making the right choice. Clin Microbiol Infect. 2009 Dec; 15 Suppl 6:5-10.
Score: 0.364
-
Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy. 2006 Mar; 26(3):347-52.
Score: 0.280
-
Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin. 2005 Dec; 21(12):1923-6.
Score: 0.276
-
A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013 Dec; 68(12):2921-6.
Score: 0.117
-
Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013 Sep; 57(9):4190-6.
Score: 0.116
-
High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011 Jun; 31(6):527-36.
Score: 0.101
-
Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007 Oct; 120(10 Suppl 1):S4-5.
Score: 0.078
-
Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect. 2005 May; 11 Suppl 3:29-35.
Score: 0.066